Humana covers Wegovy on select commercial plans but excludes it on most Medicare Advantage plans under federal anti-obesity drug rules. Coverage depends entirely on plan type, medical documentation, and whether the prescription targets weight loss or a secondary condition like cardiovascular disease or sleep apnea.
About 34% of Humana commercial employer-sponsored plans include Wegovy with prior authorization as of 2026. Medicare Advantage plans follow a stricter federal exclusion. The prior authorization process requires BMI documentation, evidence of failed diet and exercise attempts, and provider attestation. Compounded semaglutide remains a cash-pay workaround when insurance denies coverage.
This guide breaks down every Humana plan type, the exact criteria for approval, appeal success rates, and what alternatives exist when Humana says no. By the end, readers will know exactly which path fits their situation.
Does Humana Cover Wegovy for Weight Loss?
Humana covers Wegovy for weight loss on approximately 34% of its commercial employer-sponsored plans, while most Medicare Advantage plans exclude it under federal law. This is not a blanket yes or no. The answer depends entirely on which Humana plan a member holds and the documented medical reason for the prescription.
Humana explicitly excludes weight loss as a covered indication for GLP-1 medications on commercial and Medicare plans. Claims submitted with obesity diagnosis codes are rejected automatically at the pharmacy level. This is a plan exclusion, not a prior authorization denial, which means standard appeals are unlikely to succeed on excluded plans.
The core distinction lies in FDA indication. Ozempic carries FDA approval for type 2 diabetes management, while Wegovy carries FDA approval for chronic weight management and cardiovascular risk reduction. Humana covers Ozempic more readily for diabetes indications but applies stricter criteria or outright exclusions when the purpose is weight loss in non-diabetic individuals.
Does Humana Medicare Advantage Cover Wegovy?
Humana Medicare Advantage excludes Wegovy for weight loss under a federal prohibition written into the Medicare Modernization Act of 2003. Standard Medicare Part D prescription drug plans do not cover GLP-1 medications used only for weight loss.
Fewer than 8% of Humana Medicare Advantage plans include any GLP-1 coverage for weight loss as of 2026, according to CMS plan finder data. A small subset of plans offer supplemental coverage for Wegovy outside the Part D benefit, but this is rare and plan-specific. Members must check their individual plan formulary.
Starting July 2026, Humana runs the Medicare GLP-1 Bridge program. Eligible Part D members diagnosed with obesity pay a $50 copayment for each 30-day supply of covered GLP-1 medications including Wegovy. The Bridge program runs through December 2027, when the BALANCE Model is scheduled to begin.
Does Humana Commercial Insurance Cover Wegovy?
Humana commercial plan coverage for Wegovy varies by employer group and plan tier, with about 34% of commercial plans including it on formulary as of 2026. This figure rose from 18% in 2023, according to the CVS Health Formulary Trends Report.
When covered, Wegovy sits on specialty tier (Tier 4 or Tier 5) and costs $100 to $300 per month after deductible. Prior authorization is required on every plan that covers it. Members on individual and marketplace plans face the highest likelihood of exclusion, as these plans frequently exclude weight loss medications entirely unless state regulations require otherwise.
Employer-sponsored plans represent the most variable category. Some employers who use Humana as their insurance carrier have opted into GLP-1 weight loss coverage. Many have not because the cost to employers is significant. The human resources department or plan documents are the most reliable source for confirming employer-specific coverage.
How Does Humana Handle GLP-1 Coverage?
Humana requires prior authorization for GLP-1 receptor agonists across every plan type that covers them, with processing times typically ranging from 3 to 10 business days. Prior authorization means the prescribing provider must submit documentation proving medical necessity before the claim gets approved.
The documentation package typically includes BMI threshold evidence, comorbidity records, and proof of failed prior weight loss interventions. Providers must document that lifestyle modifications alone were insufficient. Missing documentation is the most common reason for initial denial.
Humana plan type comparison:
| Plan Type | Wegovy Coverage | Notes |
| Medicare Advantage (MAPD) | Excluded (most plans) | Federal law prohibits weight loss coverage; 8% of plans offer supplemental benefit |
| Commercial Employer-Sponsored | 34% of plans | Varies by employer election; prior auth required |
| Individual/Marketplace | Rarely covered | State regulations may require some coverage |
| Medicaid Managed Care | Varies by state | Some state Medicaid programs cover GLP-1s |
What Is the Prior Authorization Process for Wegovy?
The prior authorization process requires the prescribing provider to submit a structured request documenting BMI, qualifying comorbidities, and prior treatment history before Humana approves Wegovy. Members do not submit this request themselves. The provider handles it.
Required documentation typically includes a BMI of 30 or higher, or 27 or higher with at least one qualifying weight-related condition such as type 2 diabetes, hypertension, or high cholesterol. The provider must also attest that the patient attempted lifestyle modification with documented insufficient results. Processing takes 3 to 10 business days.
Members can call the number on their insurance card and ask two specific questions: whether Wegovy is on their formulary, and what the prior authorization criteria are for their specific plan. These two answers determine whether pursuing coverage is worth the effort before the provider submits paperwork.
What Step Therapy Does Humana Require?
Step therapy requires members to try and fail on one or more lower-cost medications before Humana approves coverage for Wegovy. This is a common cost-control mechanism applied to specialty tier medications.
On plans that do require step therapy, metformin or phentermine are commonly listed as first-line agents. The member must document failure on these alternatives, defined as insufficient weight loss or intolerable side effects, before Wegovy becomes eligible for coverage. Step therapy requirements vary by plan and are not universal across all Humana commercial plans.
What Are the Common Reasons Humana Denies Wegovy?
Humana denies Wegovy coverage most often because of plan exclusions for weight loss, missing documentation, BMI below the required threshold, or failure to complete step therapy requirements. Each denial reason calls for a different response strategy.
Common Humana denial reasons:
- Weight loss listed as a plan exclusion (not subject to standard appeal)
- BMI below 30 without a qualifying comorbidity at BMI 27
- Incomplete prior authorization documentation from the provider
- Missing proof of failed lifestyle interventions
- Step therapy requirements not fulfilled
- Wegovy not on the specific plan formulary
The distinction between a plan exclusion denial and a medical necessity denial matters significantly. A plan exclusion denial means Wegovy is not a covered benefit under any circumstances on that plan. A medical necessity denial means the plan covers Wegovy but the submitted documentation did not meet the criteria. Only the second type is worth appealing through standard channels.
Can You Appeal a Humana Wegovy Denial?
Yes. Members can appeal a Humana Wegovy denial, with Level 1 appeals succeeding 28% of the time and Level 2 appeals succeeding 41% of the time. But appeals only make sense when the denial is based on medical necessity, not a plan exclusion.
A successful appeal requires the provider to submit additional clinical documentation. This includes a letter of medical necessity, peer-reviewed literature supporting Wegovy for the member’s specific condition, and any updated lab results or comorbidity records not included in the original submission. The provider’s office handles the appeal submission.
When the denial is a plan exclusion, the three practical paths are: pay cash for brand-name Wegovy at $500 to $650 per month with the manufacturer savings card, switch to compounded semaglutide at $297 to $347 per month with no insurance required, or switch to a Humana plan during open enrollment that includes Wegovy on formulary.
Is There a Sleep Apnea Exception for Wegovy on Humana?
Yes. Humana Medicare may cover Wegovy off-label for obstructive sleep apnea (OSA) even when it excludes Wegovy for weight loss, under specific criteria outlined in Humana’s pharmacy policy effective January 2025.
This exception exists because the Medicare exclusion targets weight loss as the primary indication. When OSA is the primary diagnosis code on the prior authorization, the exclusion does not automatically apply. The provider must list OSA, not obesity, as the primary diagnosis when submitting the authorization request.
Wegovy is not FDA-approved for OSA. Only Zepbound (tirzepatide) received that approval in December 2024. Humana Medicare coverage of Wegovy for OSA is off-label. Off-label coverage requires all criteria to be met simultaneously. Missing even one disqualifies the member from this exception.
What Are the OSA Coverage Requirements on Humana Medicare?
Humana Medicare’s OSA exception for Wegovy requires the member to have moderate-to-severe OSA with an apnea-hypopnea index (AHI) of 15 or higher, a BMI of 30 or above, active lifestyle modification, and no type 1 or type 2 diabetes diagnosis.
The diabetes exclusion is critical. Members who have diabetes are not eligible for the OSA off-label exception. This is because Ozempic (the same active ingredient, semaglutide) is FDA-approved for diabetes and may be covered on Humana plans with prior authorization. The two pathways do not overlap.
OSA exception criteria checklist:
- Confirmed diagnosis of moderate-to-severe OSA (AHI 15 or higher)
- BMI of 30 or above at time of prior authorization
- Active participation in lifestyle modification program
- No diagnosis of type 1 or type 2 diabetes
- Prior authorization submitted with OSA (G47.33) as primary diagnosis code
What Are the Alternatives If Humana Won’t Cover Wegovy?
Members denied Wegovy coverage by Humana have three main alternatives: brand-name Wegovy on a manufacturer savings card, compounded semaglutide through a cash-pay pharmacy, or Ozempic with a diabetes diagnosis if applicable.
Brand-name Wegovy through the NovoCare savings card costs $499 per month for uninsured and underinsured individuals. Humana CenterWell Pharmacy partnered with Novo Nordisk to offer home delivery at this reduced cash-pay rate. The standard $25 per month savings card requires active insurance coverage, so members without coverage use the NovoCare program instead.
Ready to find the most affordable path to weight loss medication? Get a proven weight loss plan built around what actually works when insurance says no.
Is Compounded Semaglutide a Valid Wegovy Alternative?
Compounded semaglutide contains the same active ingredient as Wegovy and costs $99 to $347 per month on a cash-pay basis, making it the most accessible alternative when insurance denies brand-name Wegovy.
Compounded medications are not covered by insurance. Compounded semaglutide is cash-pay only, which is precisely why it functions as a workaround when insurance denies brand-name Wegovy. The FDA declared the shortage of semaglutide as resolved in February 2026, which ended the broad authorization for compounding pharmacies to produce semaglutide solutions. Members should verify current compounding pharmacy status before pursuing this route.
The clinical difference between compounded semaglutide and Wegovy centers on manufacturing standards and dosing consistency. Brand-name Wegovy undergoes rigorous FDA quality control. Compounded versions vary by pharmacy. Members should ask their provider whether compounded semaglutide is clinically appropriate for their individual situation before switching.
How Much Does Wegovy Cost With Humana Insurance?
Wegovy costs $25 to $150 per month for Humana members whose plans cover it, while cash-pay rates run $499 per month through NovoCare or $297 to $347 per month for compounded semaglutide.
When Wegovy sits on specialty tier (Tier 4 or Tier 5), cost-sharing after deductible typically runs $100 to $300 per month on Humana commercial plans. Copay amounts vary by plan design. Members on Medicare GLP-1 Bridge plans pay a flat $50 per month copayment starting July 2026. These figures assume the deductible has been met for the year.
For Humana members denied coverage, the out-of-pocket comparison matters.
Wegovy cost comparison for Humana members:
| Option | Monthly Cost | Insurance Required |
| Humana commercial (when covered) | $25 to $300 | Yes |
| Medicare GLP-1 Bridge (July 2026) | $50 | Yes (Part D plan) |
| NovoCare cash-pay brand Wegovy | $499 | No |
| Compounded semaglutide | $99 to $347 | No |
| Manufacturer savings card (insured) | $25 | Yes (active coverage) |
What Does the Wegovy Savings Card Offer?
The Wegovy manufacturer savings card reduces monthly cost to $25 for eligible patients who have active commercial insurance coverage for Wegovy, with a separate self-pay rate of $349 per month for uninsured patients through NovoCare.
The $25 per month savings card benefit requires active insurance coverage. Humana members whose plans exclude Wegovy cannot use the $25 card. The $349 per month NovoCare self-pay rate is the relevant option for excluded members. Since NovoCare also offers the same rate with simpler enrollment than the general savings card program, most Humana members denied coverage go directly through NovoCare.
Will Humana Cover Wegovy in 2027?
Humana’s coverage outlook for Wegovy in 2027 depends on federal legislative changes expected to expand Medicare GLP-1 coverage beyond the Bridge program, which runs through December 2027 before the BALANCE Model begins.
The BALANCE Model (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) is scheduled to replace the GLP-1 Bridge starting 2028. The trajectory suggests broader Medicare coverage of weight loss medications is coming. Commercial plan adoption of Wegovy rose from 18% in 2023 to 34% in 2026 and is expected to continue rising as employer cost calculations shift.
Members currently excluded from coverage have the option to check each year during open enrollment whether their plan or any comparable Humana plan has updated its Wegovy formulary status. Plan formularies can change annually. What is excluded in 2026 may be covered in 2027 on the same or a different Humana plan tier.
What Is the Medicare GLP-1 Bridge Program?
The Medicare GLP-1 Bridge program gives eligible Part D and Medicare Advantage members access to FDA-approved weight loss GLP-1 medications including Wegovy for a $50 copayment per 30-day supply starting July 2026.
To qualify for the Bridge, members must be actively enrolled in a standalone prescription drug plan or a Medicare Advantage plan with drug coverage (MAPD), be diagnosed with obesity by a doctor, and show medical need for pharmacological intervention as part of a weight management plan. The program covers Foundayo, Wegovy (injection and tablet), and Zepbound KwikPen.
The Bridge program runs through December 31, 2027. After that date, the BALANCE Model is scheduled to provide a longer-term structure for Medicare GLP-1 coverage. Members who qualify for the Bridge in 2026 should enroll promptly to lock in the $50 copayment rate during the program window.
Want Your Free Wegovy Coverage Guide From Eat Proteins?
Here is the part most people miss: knowing Humana’s rules is only half the battle. The other half is knowing exactly what to say, what to submit, and what to do when they say no. You’ve got the policy breakdown. Now you need the action plan.
Our team at Eat Proteins put together a free Wegovy coverage guide that walks through the prior authorization checklist, the appeal script that works, and the cash-pay alternatives ranked by cost. It is built for people navigating Humana and other major insurers in 2026. Don’t leave money on the table because of paperwork you didn’t know to submit.
Get the free guide sent straight to your inbox. No guesswork. Just the steps.